Overview
Many RCT(randomized controlled trial) studies reported that tranexamic acid reduced blood loss in women who had elective cesareans. However, most of these elective cesareans are without high-risk factors of postpartum hemorrhage, such as placenta previa. The prophylactic use of tranexamic acid in the placenta previa is not clear.
studies had poor quality and lacked adequate power to assess severe adverse events.
Eligibility
Inclusion Criteria:
- Age of 18 years or older
- Diagnosed with Placenta previa before cesarean delivery by ultrasound（Placenta previa defined by a placental edge below 20mm from internal cervical os diagnosed at the most recent transvaginal ultrasound examination before delivery）
- Gestational age ≥ 34 weeks
- Available venous hematocrit value in the week before the cesarean
- Prenatal hemoglobin level in the week before the cesarean > 90 g/l
- Undergoing cesarean delivery
- Signed informed consent
Exclusion Criteria:
- Known hypersensitivity to tranexamic acid or concentrated hydrochloric acid
- History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial thrombosis (angina pectoris, myocardial infarction, or stroke)
- History of epilepsy or seizure
- Any known active cancer, active cardiovascular, renal, or liver disorders
- Autoimmune diseases such as lupus, rheumatoid arthritis, Sjogren's disease, and inflammatory bowel disease
- Sickle cell disease
- Severe hemorrhagic disease
- Administration of low-molecular-weight heparin or antiplatelet agents within one week prior to delivery
- Severe coagulation disorders with prothrombin time or activated partial thromboplastin time exceeding the upper limit of normal, or platelet count less than 80×109/L
- placenta abruption
- In-utero fetal death
- Eclampsia or HELLP syndrome
- Acquired color vision deficiency or subarachnoid hemorrhage
- Severe bleeding with estimated blood loss exceeding 500 ml, within 12 hours before cesarean delivery
- Known congenital or acquired thrombophilias, including antiphospholipid antibody syndrome
- Participation in another intervention study where the primary outcome includes postpartum bleeding or thromboembolism or the study intervention potentially affects postpartum bleeding or thromboembolism